1)Nakajima T, Matsugi T, Goto W et al:New fluoroprostaglandin F(2 alpha)derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull 26:1691-1695, 2003
2)桑山泰明・米虫節夫:0.0015%DE-085(タフルプロスト)の原発開放隅角緑内障または高眼圧症を対象とした0.005%ラタノプロストとの第Ⅲ相検証的試験.あたらしい眼科 25:1595-1602,2008
3)Izumi N, Nagaoka T, Sato E et al:Short-term effects of topical tafluprost on retinal blood flow in cats. J Ocul Pharmacol Ther 24:521-526, 2008
4)石田成弘:プロスタグランジン関連薬―基礎.眼薬理 22:27-30,2008
5)Tamaki Y, Araie M, Tomita K et al:Real-time measurement of optic nerve head and choroid circulation, using the laser speckle phenomenon. Jpn J Ophthalmol 41:49-54, 1997
6)Yaoeda K, Shirakashi M, Funaki S et al:Measurement of microcirculation in the optic nerve head by laser speckle flowgraphy and scanning laser Doppler flowmetry. Am J Ophthalmol 129:734-739, 2000
7)Yaoeda K, Shirakashi M, Funaki S et al:Measurement of microcirculation in optic nerve head by laser speckle flowgraphy in normal volunteers. Am J Ophthalmol 130:606-610, 2000
8)Takagi Y, Nakajima T, Shimazaki A et al:Pharmacological characteristics of AFP-168(tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res 78:767-776, 2004
9)Ishida N, Odani-Kawabata N, Shimazaki A et al:Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev 24:1-10, 2006
10)Stjernschantz J, Selén G, Astin M et al:Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment. Prog Retin Eye Res 19:459-496, 2000
11)Boehm AG, Pillunat LE, Koeller U et al:Regional distribution of optic nerve head blood flow. Graefes Arch Clin Exp Ophthalmol 237:484-488, 1999